Latest Advisories

  • FDA Advisory No. 2014-080 || Public Warning against false, deceptive and misleading advertisement of My Jinga Juice posted in social media and the Internet

     

     

  • FDA Advisory No. 2014-079 || Voluntary Recall of Specific Batches of Arrowhead Mills Peanut Butter Products Distributed by Onestop Distribution and Healthy Options Corp

     

  • FDA Advisory No. 2014-078 || Product Recall of Lot Specific Rifampicin 450 mg Capsule (PICINAF)

     

  • FDA Advisory No. 2014-077 || Product Recall of Lot Specific Cefaclor (As Monohydrate) 50mg/mL Powder for Suspension (Oral Drops) with Brand Name CECLOBID

  • FDA Advisory No. 2014-076 || Voluntary Recall of Lot Specific Doxorubicin Hydrochloride 2 mg/mL (20 mg/10 mL) Pegylated Liposomal Concentrate for I.V. Infusion (CASPRIA)

 

    The FDA Director General, Dr. Kenneth Y. Hartigan-Go, joined the Philippine Delegates to the 67th World Health Assembly (WHA)1, led by the Secretary of Health Dr.  Enrique T. Ona and Ambassador Cecilia B. Rebong (Geneva) as co-leader.  More than 3,000 delegates from the WHO’s 194 Member States convened at the Palais des Nations in Geneva, Switzerland from May 19 to 24 in addressing key global health issues.

      The Health Secretary addressed the Assembly during the plenary debate on the relationship between climate and health, and he remarked that health is one of the most visible dimensions of climate change. He said that the health impacts of climate change are diverse and real, and that a united front against the health impacts of climate change is needed to achieve Universal Health Care (UHC) for the people.

      The delegates actively participated in meetings that adopted more than 20 resolutions on public health issues and approved a number of resolutions on issues, such as regulatory systems strengthening, access to essential medicines, AMR, public health impacts of exposure to mercury, renewed commitments to UHC, health development agenda post-2015, and health intervention and technology assessment in support of UHC, and attended various side events during the week-long conference.  

 The Philippine delegation also included Deputy Permanent Representative Noralyn Baja (Geneva), Dr. Jaime Lagahid, DOH Chief of Staff, Dr. Roland Cortez, DOH Asst. Secretary, Dr. Irma Asuncion, DPCB Director, Dr. Jose R. Llacuna, Jr., CHD-8 Director, 3rd Secretary Sharon Johnnette Agduma of the Philippine Mission (Geneva), Dr. Cirilo R. Galindez, Chief of EVRMC, Attache Michelle Eduarte (Geneva), Dr. Oscar Gutierrez, OIC-PPO, FDA, Dr. Allan Evangelista, BIHC Chief HPO, Dr. Cherylle Gavino, DOH Secretary Executive Assistant, Dr. Linda Milan, DOH Consultant, and Mr. Roger P. Tong-An, PNA National President.

 The Philippines DOH remains committed to continue and sustain its efforts in ensuring equitable, sustainable and quality health for Filipinos. Ambassador Rebong reiterated her “continued support for the work and programs of the WHO and will continue to work with the WHO in addressing global health issues,”

 

1http://www.dfa.gov.ph/index.php/2013-06-27-21-50-36/phl-embassies-and-consulates/3021-phl-joins-more-than-3-000-delegates-in-addressing-key-global-health-issues-at-67th-world-health-assembly

 During the 51st Anniversary celebration on June 23, 2014, FDA Director General Dr. Kenneth Y. Hartigan-Go, and CHD-XI Director Abdullah B. Dumama signed a Memorandum of Agreement, which would allow the FDA to use a portion of the land at the CHD-XI Office in Davao City to build the P30M FDA Regulatory Field Office in Mindanao.

The momentous event was witnessed by the FDA Deputy Director General, Dr. Ariel Valencia and the OIC of the FDA Lega Support Services Center, Atty. Donna Sanchez, together with other member of the FDA Management Team and representatives of the Cebu and Davao Satellite Laboratories.

 Assistant Secretary Romulo A. Busuego, the DOH Mindanao Cluster Head, sent his message of full support to the FDA-CHD-XI Project in Davao City. The eventual presence of the FDA, as health regulatory agency, in Mindanao would be help ensure that the people, especially the uderprivileged, have adequate and equitable access to health products, facilities and services, and will help support the government's efforts to sustained long-term economic growth and poverty reduction, as well as peace and order in the region.

Announcement

  • Scheduled Delay in Processing of Electronic Cosmetic Product Notification

    ANNOUNCEMENT

    TO : All Cosmetics Manufacturer, Traders, Distributors and other concerned parties
    DATE : 19 November 2014
    SUBJECT : Scheduled Delay in Processing of Electronic Cosmetic Product Notification
                                         (Cosmetic e-Notification)
  • QPIRA ID for Release

    ANNOUNCEMENT

    DATE        : 10 November 2014
    TO            : ALL REGISTERED QUALIFIED PERSON IN
    INDUSTRY REGULATORY AFFAIRS (QPIRA)
    FROM        :  ATTY. RONALD R. DE VEYRA, MBA, CESO VI
     Acting Deputy Director General - AFO
    SUBJECT   : QPIRA ID for Release
  • Temporary Suspension of Procurement for ITB 14-017

     BAC ADVISORY 2014-001

    for ITB 14-017

    Procurement and Delivery of One (1) Year Locked in Period and Shall be Deemed Renewed until Terminated for Consumable Supply with Fifty (50) Units Complimentary Free Use of Printers 4 in 1 Monochrome

    This is to inform all prospective bidders that the Procurement and Delivery of One (1) Year Locked in Period and Shall be Deemed Renewed until Terminated for Consumable Supply with Fifty (50) Units Complimentary Free Use of Printers 4 in 1 Monochrome (ITB 14-017) is still undergoing review of technical specification and clarifications of other requirements thus the aforementioned project is indefinitely suspended until further notice.

    Thank you.

    Read more...
  • Announcement

    For ITB 14-015

    Procurement of Supply, Delivery, Installation, Configuration Testing, Infrastructure (Hardware and Software) for One Hundred (100) VDI Users

    During the 2nd pre-bid conference, on 31 October 2014, 11AM at AFO Conference Room, FDA-Main Bldg., Alabang, Muntinlupa City, the FDA BAC will discuss with you the size of the monitor needed by the FDA end users.

    Read more...
  • Public Hearing on the New Guideline on Medical Device Registration

    Public Hearing on the New Guideline on Medical Device Registration

    TO : Medical Device Industries
    When : 3 November 2014, 9:00 am - 12:00 pm
    Public Hearing on the New Guidelines on Medical Device Registration
    Where : 3/F, AVR, Annex Building Food and Drug Administration,
    Alabang, Muntinlupa City

    For efficiency, participants shall register online through This email address is being protected from spambots. You need JavaScript enabled to view it. with the following prescribed format below:

    Email Subject  Public Hearing on the New Guideline on Medical Device Registration
    Body of Email
    Name of Participant : Last Name, First Name, MI.
    Company Name  
    Contact No(s)  
    Email Address  

    A confirmation slip will be sent as a reply, please bring a copy of your confirmation slip on the day of Public Consultation

    For your information, guidance, and compliance

Videos

  • Win the War Againts AMR

    The misuse of antibiotics is creating resistant "superbugs" that may leave you or your family without effective treatment the next time antibiotics are needed.

  • FDA Public Assistance Information and Receiving (PAIR) Video Tutorial

    A step by step guide to filing an application for a License to Operate or a Certificate of Product Registration.
    By: Nicole Melanie Molera

  • Dr. Kenneth Hartigan-Go on Responsible Pharmaceutical Manufacturing by Interphil

    Dr. Kenneth Hartigan-Go talks about importance of CGMP in manufacturing pharmaceutical products, bioequivalence, importance of adverse drug monitoring, and ethical marketing communications.

Share Us on

Submit to FacebookSubmit to Google BookmarksSubmit to Twitter